Adalta Ltd has released a press release.
Rights Offer results
Filed with ASX ·
6ix hasn’t read this filing yet.
In the deck
Earlier from AdAlta
- AdAlta to support early return to clinical trials of AD-214 with rights offer
- Rights Offer to fund early return to clinic and growth
- Publication highlights I-body potential in osteoporosis
- AdAlta welcomes new substantial shareholders
- Second Japan patent for AD-214
Later from AdAlta
- AdAlta secures A$1.28 million in rights offer to advance AD-214
- AdAlta to present at June 1 Virtual Investor Summit
- AD-214 clinical trial approval
- New AD-214 data de-risks clinical studies
- $1.87 million raised in oversubscribed Shortfall facility
Follow AdAlta into a list and get an email when it puts out news.
Follow AdAlta